Children's Oncology Group's 2023 blueprint for research: Renal tumors

Abstract

AbstractEvery year, approximately 600 infants, children, and adolescents are diagnosed with renal cancer in the United States. In addition to Wilms tumor (WT), which accounts for about 80% of all pediatric renal cancers, clear cell sarcoma of the kidney, renal cell carcinoma, malignant rhabdoid tumor, as well as more rare cancers (other sarcomas, rare carcinomas, lymphoma) and benign tumors can originate within the kidney. WT itself can be divided into favorable histology (FHWT), with a 5‐year overall survival (OS) exceeding 90%, and anaplastic histology, with 4‐year OS of 73.7%. Outcomes of the other pediatric renal cancers include clear cell sarcoma (5‐year OS: 90%), malignant rhabdoid tumor (5‐year OS: 10% for stages 3 and 4), and renal cell carcinoma (4‐year OS: 84.8%). Recent clinical trials have identified novel biological prognostic markers for FHWT, and a series of Children's Oncology Group (COG) trials have demonstrated improving outcomes with therapy modification, and opportunities for further care refinement.